Picture courtesy The News Minute
New Delhi: The supply price of COVID-19 vaccine Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run, Bharat Biotech said on Tuesday.
The Centre’s supplying price is pushing the pricing structure for the private sector upward, the vaccine maker said, justifying Covaxin’s higher price when compared to other COVID-19 vaccines available for the private sector in India.
According to the company, fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among others were contributing to higher pricing of Covaxin.
“The supply price of Covaxin to the government of India at Rs 150 per dose is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” Bharat Biotech said in a statement.
Angul: Three persons were killed after a truck dashed against the motor-cycle they were riding…
New Delhi: Gurcharan Singh, who played ' Sodhi' in the popular TV show 'Taarak Mehta…
New Delhi: Delhi Chief Minister and Aam Aadmi Party (AAP) convenor Arvind Kejriwal's wife Sunita…
Koraput: The forthcoming Assembly elections in Pottangi of Odisha’s Koraput district is likely to witness…
New Delhi: A high-ranking officer of the Central Reserve Police Force (CRPF) has been dismissed…
New Delhi: The second phase of polling for Lok Sabha elections was held ‘smoothly and peacefully’…
Bhubaneswar: Odisha unit of BJP on Friday alleged that Chief Minister Naveen Patnaik is contesting…
London: New data has emerged about a more virulent strain of monkeypox virus. And what…